Integrating ctDNA With Emerging Biomarkers

This segment explores how ctDNA can be integrated with other emerging biomarkers, particularly in germ cell tumors. Panelists discuss how ctDNA complements traditional serum tumor markers such as AFP and hCG, offering improved prognostic insight in certain clinical scenarios. The potential role of ctDNA in evaluating residual masses and guiding decisions about further intervention is also highlighted. Additionally, microRNA-based assays are discussed as promising tools that may enhance molecular monitoring when used alongside ctDNA. While these approaches show significant potential, clinicians emphasize that they remain investigational and should currently be used in conjunction with established markers. This segment reflects the broader movement toward multimodal molecular monitoring to improve precision and personalization in GU oncology.